Showing 1 - 1 results of 1 for search 'Hannah Moatti', query time: 0.61s
Refine Results
-
1
P109: One-Day Brentuximab-Bendamustine (120mg/m2) every 21 days is a feasible and safe treatment for relapsed/refractory Hodgkin lymphoma by Hannah Moatti, Marie-Céleste Laroque, Loïc. Renaud, Odonchimeg Ravdan, Charlotte Schmidt-Hieber, Isabelle Madelaine, Roberta Di Blasi, Catherine Thieblemont, Pauline Brice
Published 2022-10-01
Article